Displaying drugs 15026 - 15050 of 15772 in total
Antithrombin gamma
Antithrombin gamma is under investigation in clinical trial NCT04182373 (KW-3357 Study in Patients With Early Onset Severe Preeclampsia).
Investigational
Cemdisiran
Cemdisiran is under investigation in clinical trial NCT03841448 (A Study of Cemdisiran in Adults With Immunoglobulin a Nephropathy (Igan)).
Investigational
Befovacimab
Investigational
INVAC-1
INVAC-1 is under investigation in clinical trial NCT03265717 (DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (Htert), Invac-1 in Chronic Lymphocytic Leukemia).
Investigational
IONIS-HBVRx
IONIS-HBVRx is under investigation in clinical trial NCT04544956 (A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B).
Investigational
B27PD
B27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).
Investigational
Rinucumab
Rinucumab is under investigation in clinical trial NCT02418754 (Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-related Macular Degeneration (AMD)).
Investigational
siG12D LODER
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
STX-100
STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).
Investigational
BGB-DXP593
BGB-DXP593 is a SARS-CoV-2 neutralizing antibody. It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene.
Investigational
Camidanlumab tesirine
Camidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).
Investigational
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to the hepatitis B surface antigen . Virus-like particles (VLPs) are protein-based vaccines that stimulate high immune responses because of the VLPs’...
Investigational
AG0302-COVID19
Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
Investigational
Rexin G
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
Investigational
Lactobacillus salivarius
Experimental
Medicago sativa top
Experimental
Nux vomica extract
Experimental
Mentha arvensis leaf oil
Experimental
Pelargonium sidoides root
Experimental
Pinus densiflora whole
Experimental
Thyme oil
Experimental
Bee pollen
Experimental
Krill oil
Experimental
Lithothamnion calcareum extract
Experimental
Botensilimab
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
Investigational
Displaying drugs 15026 - 15050 of 15772 in total